Antiverse and GlobalBio, Inc. extend collaboration to advance antibody cancer therapeutics October 25, 2023
First Patients Dosed in First-in-Human Ph 1 Study of FX-909 in Advanced Solid Tumors, Including Urothelial Cancer October 25, 2023
Interim PK/PD and Clinical Data for MRT-2359 in Ph 1/2 Trial for MYC-Driven Solid Tumors announced October 25, 2023
MediLink Therapeutics Announces Strategic Collaboration And Worldwide License Agreement With BioNTech To Develop Next-Gen Anti-Cancer ADCs October 18, 2023
Clinical trials of nanrilkefusp alfa as monotherapy and in combinations with pembrolizumab and cetuximab to be discontinued October 18, 2023
Updated PC14586 Ph 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation October 16, 2023
Positive Preliminary Data from Ph 1 Dose Escalation Portion of Ph 1/2 KB-0742 Study presented October 16, 2023
Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors announced October 16, 2023
Ankyra Therapeutics and Merck to Evaluate ANK-101 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors October 11, 2023
1ST Biotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate FB849 in Combination With KEYTRUDA September 26, 2023
Boundless Bio Announces Clinical Trial Collaboration & Supply Agreement with Taiho Oncology to Evaluate LYTGOBI + BBI-355 in Patients with FGFR Amplified Solid Tumors September 26, 2023
Boundless Bio Announces Clinical Trial Collaboration & Supply Agreement with Lilly to Evaluate VERZENIO + BBI-355 in Patients with CDK4/6 Amplified Solid Tumors September 26, 2023
Debiopharm and SunRock Biopharma Partner to Advance Antibody Drug Conjugates for Hard-to-treat Cancers September 26, 2023
Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091 September 19, 2023
Nurix Announces Strategic Collaboration with Seagen Combining Technologies of Targeted Protein Degradation and Antibody-Drug Conjugation to Advance a New Class of Cancer Therapeutics September 19, 2023
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics September 19, 2023
AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology September 19, 2023
KSQ Therapeutics and CTMC Announce Strategic Collaboration to Accelerate the Development of Novel Engineered Tumor Infiltrating Lymphocyte (eTIL) Therapies for the Treatment of Solid Tumors September 13, 2023
Portage Biotech announces collaboration with Merck to evaluate two next-generation adenosine antagonists in combination with Keytruda® in solid tumors September 13, 2023
OncoNano and Regeneron Enter into Clinical Trial Supply Agreement for Use of Libtayo® (cemiplimab) in ONM-501 Study September 13, 2023
